Survival rates for newly diagnosed Lymphoma patients steadily rising

A new article in US News & World Report says blood cancer patients are living longer today than they were in the 1980s.

Well I should hope so.

The study, to be published in the journal Cancer in November, examined data taken from the Surveillance, Epidemiology and End Results (SEER) database—a US cancer registry. More to the point, they compared patients with five types of blood cancer from two five-year stretches: 1981-1985 and 2001-2005. Here's what they found (expressed in ten-year survival rates):

- Hodgkin's: Up almost 13 percent (80.4 % to 93.4 %)
- Non-Hodgkin's: Up over 20 percent (55.6 % to 76.2 %)
- Acute lymphoblastic leukemia: Up over 21 percent (30.5 % to 52.1 %)
- Acute myeloblastic leukemia: Up almost 30 percent (15.2 % to 45.1 %)
- Chronic myelocytic leukemia: Up 74.5 percent (0 % to 74.5 %)

The good news for all lymphoma patients is that survival rates have been rising pretty steadily in that time—as opposed to the acute leukemias, as those 10-year survival rates haven't changed much since the late 1990s.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap